{"title":"Candidiasis as a Potential Marker of Imminent Mortality in Palliative Care: A Retrospective Observational Study.","authors":"Andreia Mandim, Licinia Araújo, Susete Freitas","doi":"10.1177/26892820251374977","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Predicting short-term mortality in patients receiving palliative care can help tailor interventions, manage expectations, and improve end-of-life planning. This study explores whether candidiasis, particularly in patients on corticosteroids, is associated with increased 30-day mortality.</p><p><strong>Methods: </strong>We conducted a retrospective study of patients admitted to a specialized palliative care unit in 2022. Data collected included demographics, candidiasis diagnosis (oral/esophageal), corticosteroid use, and mortality. Patients with candidemia were excluded. Of 59 deaths in the unit, 35 had complete records and met inclusion criteria.</p><p><strong>Results: </strong>Of the 35 patients analyzed, 71.4% were female; the median age was 61. Ten patients developed candidiasis, all with advanced cancer and functional decline. Among candidiasis cases, 30-day mortality was 60% versus 0% in those without. Median time from candidiasis diagnosis to death was 19 days. Among corticosteroid users, candidiasis was associated with significantly higher short-term mortality.</p><p><strong>Conclusions: </strong>Candidiasis in patients receiving palliative care-particularly those on corticosteroids-may indicate imminent death. These findings suggest its potential as a simple prognostic marker in resource-limited settings, meriting further prospective validation.</p>","PeriodicalId":74394,"journal":{"name":"Palliative medicine reports","volume":"7 ","pages":"26892820251374977"},"PeriodicalIF":1.3000,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443232/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Palliative medicine reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/26892820251374977","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Predicting short-term mortality in patients receiving palliative care can help tailor interventions, manage expectations, and improve end-of-life planning. This study explores whether candidiasis, particularly in patients on corticosteroids, is associated with increased 30-day mortality.
Methods: We conducted a retrospective study of patients admitted to a specialized palliative care unit in 2022. Data collected included demographics, candidiasis diagnosis (oral/esophageal), corticosteroid use, and mortality. Patients with candidemia were excluded. Of 59 deaths in the unit, 35 had complete records and met inclusion criteria.
Results: Of the 35 patients analyzed, 71.4% were female; the median age was 61. Ten patients developed candidiasis, all with advanced cancer and functional decline. Among candidiasis cases, 30-day mortality was 60% versus 0% in those without. Median time from candidiasis diagnosis to death was 19 days. Among corticosteroid users, candidiasis was associated with significantly higher short-term mortality.
Conclusions: Candidiasis in patients receiving palliative care-particularly those on corticosteroids-may indicate imminent death. These findings suggest its potential as a simple prognostic marker in resource-limited settings, meriting further prospective validation.